Streetbeat News

Equity Actions

KSM

The DWS Strategic Municipal Income Trust has approved its termination and will proceed with a liquidating distribution to its shareholders. This decision marks the end of the trust's operations, transitioning to the final phase of liquidation.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:42 pm

RNAC

Cartesian Therapeutics announced the approval of the conversion of Series A Convertible Preferred Stock and plans to implement a reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:40 pm

AVBP

ArriVent BioPharma reported a FY23 EPS of $(32.38), compared to $(28.90) in FY22. R&D expenses increased to $64.9M, mainly due to furmonertinib trials. G&A expenses rose to $9.7M, attributed to costs of operating as a public company and higher personnel costs. The net loss widened to $69.3M from $37.0M. However, with $150.4M in cash and upcoming IPO proceeds, the company expects to fund operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:38 pm

PLSE

Pulse Biosciences' stock is trading lower following the announcement of its Q4 financial results and plans to initiate a rights offering of up to $60 million worth of units.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:30 pm

GAME

GameSquare Holdings, Inc. (NASDAQ:GAME) has completed its voluntary delisting from the TSX Venture Exchange (TSXV) as of March 28, 2024. The delisting does not impact GameSquare's NASDAQ listing, where its shares continue to trade under the symbol 'GAME'.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:28 pm

AUTL

Autolus Therapeutics Plc has filed for the resale of up to 33.33 million shares by the selling securityholder, as indicated in their S-3ASR filing.

Portfolio Pulse from Charles Gross

March 28, 2024 | 8:22 pm

AERT

Bhisham Khare has reported a 9.83% ownership stake in Aeries Technology, indicating a significant investment in the company. This move could signal confidence in Aeries Technology's future prospects or strategic interests by Khare.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:17 pm

RNAC

Cartesian Therapeutics, Inc. (NASDAQ:RNAC), a biotech company, announced the approval of the conversion of its Series A Convertible Preferred Stock and a 1-for-30 reverse stock split effective after trading hours on April 4, 2024. The conversion will occur on April 8, 2024, and the reverse stock split will see the company's common stock trade on a split-adjusted basis starting April 5, 2024. This will reduce the number of outstanding shares from approximately 165.5 million to about 5.5 million before the conversion, and approximately 23.3 million shares after all conversions.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:16 pm

OTLK

Tang Capital Partners has disclosed a 9.99% passive stake in Outlook Therapeutics, indicating a significant investment in the company.

Portfolio Pulse from Benzinga Newsdesk

March 28, 2024 | 8:16 pm

ED

Consolidated Edison's (NYSE:ED) short interest has increased by 7.06% since the last report, with 6.99 million shares sold short, representing 2.73% of its float. This indicates a bearish market sentiment, although it's below the peer group average of 3.27%. The article suggests that an increase in short interest doesn't necessarily predict a stock price fall.

Portfolio Pulse from Benzinga Insights

March 28, 2024 | 8:15 pm